ืืืชืืจืื ืืืชื ืืชืืืืืืช ืืืจืืช ืฆืืื ืจืคืืื ืืขืช ืืืกืืฃ ืื ืชืื ืื ืืงืืื ืืื ืืืืจ ืงืืืช ืืืืฉืืจ ืืจืืืืืืจื (CE, FDA, AMAR)
(PhD) ื"ืจ ื ืืืื ืืืจืฉืืืื
- ืืื ืืคืชื ืืกืืจืืืืช PMCF ื ืืื ื ืืืืืืงืช ืืืืฆืจ ืฉืื.
- ืืื ืืชืื ื ืืืืฆืข ืืืงืจืื ืงืืื ืืื ืืกืืืืช postmarketing.
- ืืื ืืืืขืืจ ืืืืจืืื ื ืืกืคืื (ืืฉืงืืขืื, ืจืืคืืื, ืืคืืฆืื, ืจืฉืืืืช) ืืื ืืืฆืืื ื- postmarketing study.
- ืืื ืืื ืืช clinical evidence ืืืง ืืื ืืืฆืืข ืืืงืจ ืงืืื ื.
ื”ืจ ื ืืืื ืืืจืฉืืืื ย (PhD),ืืขืืช ื ืกืืื ืฉื ืืืขืื ย ื-25 ืฉื ื ืืชืขืฉืืืช ืืืืงืจ ืืงืืื ื ืืชืืืื ืืฆืืื ืืจืคืืื, ืคืืจืื, ืืืืืื ืืืืื, ืืชืขืฉืื ืืืงืืืืช ืืืืื ืืืืืืช.
ืื ืืืช ืคืจืืืงืืื ืงืืื ืืื ืืคืืชืื ืืกืืจืืืืืช ืงืืื ืืืช ืืื ืืจืฉืืืืช ืืืจื”ื ืืืืจืืคื.- 21.05.24 ืืื ืฉืืืฉื
- 14:00-15:00
ืืืืืื ืจ ืืื ืืืจ ื ืขืจื, ืืื ืืงืื ืงืืฉืืจ ืืฆืคืืื ืืืืืื ืจ ืืืืงืื ืื ื “ืฆืืจ ืงืฉืจ” ืืืงืฉ ืืงืืื ืืก’ 102.
This Webinar was already held, to receive a link to watch the recorded Webinar
please contact usย and ask for recording No.#102.